Items Tagged with 'Pfizer'
Purchase ceiling raised for two stock picks.
In light of significant recent developments, The Turnaround Letter is raising its maximum buy price for these large cap purchase recommendations.Read More
PFE Complete $11.85 billion Sale
On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.
PFE Announces Revenues of $14.0 billion
On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion
On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.
PFE Obtains FDA Approval for Lyrica
On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
PFE Reports 7% Revenue Decrease
On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.
PFE to Divest Nutrition Business
On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.
Pfizer Buys Vitamin C Icon
On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....
On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.
On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Learn George Putnam's Turnaround Secrets
Turnaround Investing Blog
With U.S. stocks well into their eighth year of a bull market and the economy showing increasing signs of strength, finding ideal turnaround stocks--those with all three ingredients--can be a needle-in-the-haystack project at best. What is an investor to do in a seemingly barren value stock landscape?
Market-Beating Profit: The 200+ Club
Turnaround stocks present a unique opportunity for savvy investors to buy in at bargain prices. Take a look at this list of just a few of our purchase recommendations that have realized a return rate of 200% or better:
* Bristow remains in our active portfolio (currently as a Hold), and 2,057% gain is as of 11/9/16.
Bet on These Battered Stocks
Chicago Tribune highlighted this Kiplinger's Money Power write-up on George's contrarian investing approach and The Turnaround Letter's April 2016 monthly turnaround stock pick.
Darren Fonda notes, "…besieged stocks often start to recuperate as the headlines fade and investors anticipate a return to precrisis sales and profits. The trick, of course, is to find companies that are more likely to rebound from a setback than collapse entirely."
Learn more about Putnam's turnaround investing strategy.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.